KIAA1199 provides a connection between oncogenic signaling of NF-κB and EGFR

 

Tumor generation and progression are regulated by a series of signaling pathways mediating cell proliferation and survival. EGFR and NF-κB signaling cascades are main pathways involved in those actions. Shostak et al. showed the connection between the two oncogenic cascades by identifying a key factor, KIAA1199, that associated with human papillomavirus (HPV) infection. The article was published on Nature Communications, recently.

 

Several proteins responsible for oncogenic siganlling of NF-κB, including p50, p65 and BCL-3. Researchers found BCL-3 and p65 were able to induce expression of KIAA1199 in HPV-positive cells and in cervival (pre)neoplastic lesions. Then, KIAA1199 was proved to bind Plexin A2 and counteract Semaphroin 3A-mediated cell death by enhancing stability of EGFR signaling. In addition, researchers found KIAA1199 limited cell apoptosis not only by down-regulating Semaphroin 3A, but also by inactivating Tumour necrosis factor-α (TNFα) pathway, which is negatively regulated by EGFR signaling. Moreover, KIAA1199 up-regulates EGF-mediated epithelial-mesenchymal transition (EMT) in cervical cencer-derived CaSki cells. In summary, this study indicates that KIAA1199, induced by HPV infection, acts as a linker between NF-κB and EGFR signaling pathways in promoting cancer cell proliferation, survival and invasive.

 

Reference:
Nat Commun. 2014 Nov 4;5:5232.

Related Products

Cat.No.	Product Name	Information
S1011	Afatinib	Afatinib inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFRwt, EGFR L858R , EGFR L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
S1023	Erlotinib HCl	Erlotinib HCl is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

Related Targets

NF-κB EGFR